Osteo Arthritis of the Knees
Conditions
Brief summary
There has been intensive search for a substance that can have disease-modifying activity for osteoarthritis. A number of medications have been reported to be of benefit on slowing progression of knee OA. This trial will be the first head to head comparison of these medications. Patients aged between age 40 to 65 will be enrolled. Patients will be assessed clinically using two scoring systems, the WOMAC index for knee arthritis and the SF 36 for overall physical and mental health. The knee X rays will be assessed on Kellgren and Lawrence grading and will also be measured for joint space narrowing at follow up. The response to arthritis medications on slowing down cartilage loss will be measured biochemically with COMP levels.
Interventions
Sponsors
Indus Hospital and Health Network
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients of either sex aged between 40 to 65 years with mild to moderate osteoarthritis of the knees. * Patients should have history of knee pain for at least 6 months and on the majority of days during the preceding month * Each joint will be scored separately so one patient with bilateral knee osteoarthritis will be counted as 2 knees. * The osteoarthritis will be graded on basis of clinical score as well as seen on appropriately positioned x rays using the Kellgren and Lawrence grading. (Tibio femoral osteophytes of at least 1 mm, Kellgren Lawrence grading of 2 or 3) * Patients with diabetes are sent to the diabetes clinic and are included once their HbA1c level becomes normal. * Patients giving Informed consent
Exclusion criteria
* Patients with severe end stage tricompartmental osteoarthritis of the knees . * Presence of uncontrolled systemic disease like chronic liver and renal disease * Patients with diagnosis other than osteoarthritis, such as knee arthritis due to rheumatoid disease, gout, post traumatic arthritis * Patients with history of surgery to any knee will have that knee excluded * Pregnant or lactating mothers * Patients with chronic anaemia * Patients who get an injection in their affected knee
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in WOMAC score at 24 months in comparison to baseline score | baseline, 24 months | Hypothesis:- At least one of the intervention drug will result in an improvement of at least 20 points on the WOMAC score at end of 2 years as compared to the placebo when compared to base line score |
| Change to the SF-36 score at 24 months in comparison to baseline score | 24 months | Hypothesis: At least one of the intervention drugs will result in an improvement of at least 20 points at end of two years when assessed using the SF36 total score as compared to the standard therapy placebo when compared with baseline score |
| Mean differences in blood serum COMP levels of study arms | 24 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Change to the SF-36 score at 6 months in comparison to baseline score | 6 months |
| Change in WOMAC score at 6 months in comparison to baseline score | 6 months |
| Change to the SF-36 score at 18 months in comparison to baseline score | 18 months |
| Change to the SF-36 score at 12 months in comparison to baseline score | 12 months |
| Change in WOMAC score at 12 months in comparison to baseline score | 12 months |
| Change in WOMAC score at 18 months in comparison to baseline score | 18 months |
Countries
Pakistan
Outcome results
None listed